Adjuvant Therapy in Breast Cancer – Have We Already Learned the Entire Lesson?

[摘要] At first glance, adjuvant therapy of early breast cancer appears to be a dull topic: the major players are set and have not changed significantly over the last years: chemotherapy, endocrine therapy and HER2 targeted therapy. While during the 1990ies and 2000s a wealth of new substances, such as taxanes, aromatase inhibitors, new-generation bisphosphonates, and HER2 targeted agents, were introduced into the treatment of primary breast cancer, little has been added to this portfolio of substances since then. Indeed, in Europe no new drug has been approved by the EMA for the treatment of early breast cancer during this decade.

[学科分类] 泌尿医学